Tags

Type your tag names separated by a space and hit enter

Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects.
Chest. 1990 Aug; 98(2):276-9.Chest

Abstract

Bronchial hyperresponsiveness is one of the major clinical features of bronchial asthma. We previously reported that oral administration of a selective thromboxane synthetase inhibitor, OKY-046, reduced bronchial hyperresponsiveness to acetylcholine in asthmatic subjects. In this study, the effect of aerosol administration of OKY-046 on bronchial hyperresponsiveness was evaluated in ten inpatients with intrinsic asthma. Acetylcholine inhalation tests were performed before and after four days of inhalation of OKY-046 (100 mg/day). The provocative concentration of acetylcholine producing a 20 percent fall in forced expiratory volume in 1 s (PC20-FEV1) and that causing a 35 percent fall in respiratory conductance (PC35-Grs) were measured as indexes of bronchial responsiveness. There was a significant increase in PC20-FEV1 (p less than 0.001) and PC35-Grs (p less than 0.02) after inhalation of OKY-046 from 0.79 (GSEM, 1.41) Mg/ml and 0.96 (GSEM, 1.35) mg/ml to 1.20 (GSEM, 1.41) mg/ml and 1.74 (GSEM, 1.32) mg/ml, respectively. There was no significant difference in forced vital capacity (FVC), FEV1, or respiratory resistance (Rrs) baseline values before and after inhalation of OKY-046. Platelet aggregation was not inhibited by the treatment in other five inpatients. Thus, prophylactic administration of aerosol OKY-046 may be available for treatment of asthma by reduction of bronchial hyperresponsiveness. Further studies are needed to determine the optimum dose.

Authors+Show Affiliations

Third Department of Internal Medicine, Kanazawa, University School of Medicine, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2376157

Citation

Fujimura, M, et al. "Effects of Aerosol Administration of a Thromboxane Synthetase Inhibitor (OKY-046) On Bronchial Responsiveness to Acetylcholine in Asthmatic Subjects." Chest, vol. 98, no. 2, 1990, pp. 276-9.
Fujimura M, Nishioka S, Kumabashiri I, et al. Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects. Chest. 1990;98(2):276-9.
Fujimura, M., Nishioka, S., Kumabashiri, I., Matsuda, T., & Mifune, J. (1990). Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects. Chest, 98(2), 276-9.
Fujimura M, et al. Effects of Aerosol Administration of a Thromboxane Synthetase Inhibitor (OKY-046) On Bronchial Responsiveness to Acetylcholine in Asthmatic Subjects. Chest. 1990;98(2):276-9. PubMed PMID: 2376157.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects. AU - Fujimura,M, AU - Nishioka,S, AU - Kumabashiri,I, AU - Matsuda,T, AU - Mifune,J, PY - 1990/8/1/pubmed PY - 1990/8/1/medline PY - 1990/8/1/entrez SP - 276 EP - 9 JF - Chest JO - Chest VL - 98 IS - 2 N2 - Bronchial hyperresponsiveness is one of the major clinical features of bronchial asthma. We previously reported that oral administration of a selective thromboxane synthetase inhibitor, OKY-046, reduced bronchial hyperresponsiveness to acetylcholine in asthmatic subjects. In this study, the effect of aerosol administration of OKY-046 on bronchial hyperresponsiveness was evaluated in ten inpatients with intrinsic asthma. Acetylcholine inhalation tests were performed before and after four days of inhalation of OKY-046 (100 mg/day). The provocative concentration of acetylcholine producing a 20 percent fall in forced expiratory volume in 1 s (PC20-FEV1) and that causing a 35 percent fall in respiratory conductance (PC35-Grs) were measured as indexes of bronchial responsiveness. There was a significant increase in PC20-FEV1 (p less than 0.001) and PC35-Grs (p less than 0.02) after inhalation of OKY-046 from 0.79 (GSEM, 1.41) Mg/ml and 0.96 (GSEM, 1.35) mg/ml to 1.20 (GSEM, 1.41) mg/ml and 1.74 (GSEM, 1.32) mg/ml, respectively. There was no significant difference in forced vital capacity (FVC), FEV1, or respiratory resistance (Rrs) baseline values before and after inhalation of OKY-046. Platelet aggregation was not inhibited by the treatment in other five inpatients. Thus, prophylactic administration of aerosol OKY-046 may be available for treatment of asthma by reduction of bronchial hyperresponsiveness. Further studies are needed to determine the optimum dose. SN - 0012-3692 UR - https://www.unboundmedicine.com/medline/citation/2376157/Effects_of_aerosol_administration_of_a_thromboxane_synthetase_inhibitor__OKY_046__on_bronchial_responsiveness_to_acetylcholine_in_asthmatic_subjects_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(16)31638-5 DB - PRIME DP - Unbound Medicine ER -